Floatz Rating
CCC54/100
Confidence
Indicative
Sponsor
Columbia University
Modality
UNKNOWN
Development Phase
Phase 2/3
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
39Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT01019876CT.gov Risk-Adapted Allogeneic Stem Cell Transplantation For Mixed Donor Chimerism In Patients With Non-Malignant Diseases | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Fanconi Anemia
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Horse Anti-Thymocyte Globulin (this asset) | Columbia University | P2/3 | CCC · 54 |
| Cyclophosphamide | Porteus, Matthew, MD | P2/3 | BBB |
| Fludarabine | Porteus, Matthew, MD | P2/3 | BBB |
| Busulfanum | Masonic Cancer Center, University of Minnesota | P2/3 | BBB |
| Cyclosporin A | Fred Hutchinson Cancer Center | P2 | BBB |
| Nivestim | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | P2 | BBB |
| Prednisone | Fred Hutchinson Cancer Center | P2 | BB |
| Plerixafor | Assistance Publique - Hôpitaux de Paris | P2 | BB |
| Alemtuzumab | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | P2/3 | BB |
+34 more in the Fanconi Anemia cohort
Other indications for Horse Anti-Thymocyte Globulin
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Bone Marrow Failure Syndrome | — | P2/3 | B · 62 |
| Immunodeficiency Disease | — | P2 | B · 56 |
| Severe Combined Immunodeficiency | — | P2/3 | CCC · 54 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Horse Anti-Thymocyte Globulin in Fanconi Anemia. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/horse-anti-thymocyte-globulin-fanconi-anemia
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →